| Literature DB >> 31416127 |
Wanhyung Lee1, Mo-Yeol Kang2, Jin-Ha Yoon3,4.
Abstract
BACKGROUND: There are increasing concerns regarding increased cancer risks in professional flight attendants due to their exposure to occupational hazards that are known or suspected to be carcinogenic. In this study, we aimed to analyze various cancer risks among a cohort of Korean air transportation industry workers.Entities:
Keywords: air transportation industry workers; leukemia; neoplasms
Mesh:
Substances:
Year: 2019 PMID: 31416127 PMCID: PMC6727080 DOI: 10.3390/ijerph16162906
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
The characteristics of the study participants at the baseline of cohort.
| Person-year, % | ||||||
|---|---|---|---|---|---|---|
| Air Transportation Industry Workers | Government Employee | Whole Employee | ||||
| Total person-years | 59,751 | 5,678,047 | 85,954,378 | |||
| Gender | ||||||
| Male | 45,673 | 76.4 | 2,898,213 | 51.0 | 57,871,482 | 67.3 |
| Female | 14,078 | 23.6 | 2,779,834 | 49.0 | 28,082,896 | 32.7 |
| Age | ||||||
| Total | ||||||
| 25–30 | 5980 | 10.0 | 290,037 | 5.1 | 9,240,276 | 10.8 |
| 31–35 | 11,398 | 19.1 | 722,694 | 12.7 | 15,509,508 | 18.0 |
| 36–40 | 12,109 | 20.3 | 974,979 | 17.2 | 16,435,257 | 19.1 |
| 41–45 | 10,330 | 17.3 | 1,054,586 | 18.6 | 14,852,909 | 17.3 |
| 46–50 | 8719 | 14.6 | 1,056,016 | 18.6 | 12,825,823 | 14.9 |
| 51–55 | 7108 | 11.9 | 920,516 | 16.2 | 10,270,762 | 11.9 |
| 56–60 | 4107 | 6.9 | 659,219 | 11.6 | 6,819,843 | 7.9 |
| Male | ||||||
| 25–30 | 2378 | 5.2 | 57,160 | 2.0 | 4,240,331 | 7.3 |
| 31–35 | 6997 | 15.3 | 210,875 | 7.3 | 9,019,025 | 15.6 |
| 36–40 | 9883 | 21.6 | 390,711 | 13.5 | 11,470,377 | 19.8 |
| 41–45 | 9102 | 19.9 | 516,571 | 17.8 | 10,897,150 | 18.8 |
| 46–50 | 7615 | 16.7 | 615,957 | 21.3 | 9,434,555 | 16.3 |
| 51–55 | 6121 | 13.4 | 622,025 | 21.5 | 7,639,526 | 13.2 |
| 56–60 | 3577 | 7.8 | 484,914 | 16.7 | 5,170,518 | 8.9 |
| Female | ||||||
| 25–30 | 3602 | 25.6 | 232,877 | 8.4 | 4,999,945 | 17.8 |
| 31–35 | 4401 | 31.3 | 511,819 | 18.4 | 6,490,483 | 23.1 |
| 36–40 | 2226 | 15.8 | 584,268 | 21.0 | 4,964,880 | 17.7 |
| 41–45 | 1228 | 8.7 | 538,015 | 19.4 | 3,955,759 | 14.1 |
| 46–50 | 1104 | 7.8 | 440,059 | 15.8 | 3,391,268 | 12.1 |
| 51–55 | 987 | 7.0 | 298,491 | 10.7 | 2,631,236 | 9.4 |
| 56–60 | 530 | 3.8 | 174,305 | 6.3 | 1,649,325 | 5.9 |
The age-standardized incidence ratios (SIR) and 95% confidence interval (CI) of the air transportation industry male workers for cancers according to the reference group.
| Cancer | ICD-10 | Reference, SIR (95% CI) for Cancers | |
|---|---|---|---|
| Government Employee | Whole Employee | ||
| All cancer | 0.58 (0.54–0.62) | 0.57 (0.53–0.61) | |
| Gastrointestinal tract system | |||
| Malignant neoplasms of lip, oral cavity, and pharynx | C00–C14 | 0.58 (0.25–1.13) | 0.56 (0.24–1.11) |
| Malignant neoplasm of esophagus | C15 | 0.59 (0.19–1.37) | 0.69 (0.22–1.61) |
| Malignant neoplasm of stomach | C16 | 1.16 (0.98–1.35) | 1.09 (0.93–1.28) |
| Malignant neoplasm of colon | C18 | 0.96 (0.73–1.25) | 1.04 (0.79–1.36) |
| Malignant neoplasms of rectosigmoid junction, rectum, anus, and anal canal | C19–C21 | 0.93 (0.67–1.27) | 0.84 (0.60–1.14) |
| Malignant neoplasm of liver and intrahepatic bile ducts | C22 | 1.13 (0.90–1.39) | 1.02 (0.82–1.26) |
| Malignant neoplasm of pancreas | C25 | 0.52 (0.23–1.04) | 0.51 (0.22–1.00) |
| Other malignant neoplasms of digestive organs | C17, C23–C24, C26 | 0.72 (0.34–1.32) | 0.64 (0.31–1.17) |
| Respiratory system | |||
| Malignant neoplasm of larynx | C32 | 0.85 (0.23–2.16) | 0.80 (0.22–2.06) |
| Malignant neoplasm of trachea, bronchus, and lung | C33–C34 | 1.14 (0.86–1.49) | 1.00 (0.75–1.30) |
| Other malignant neoplasms of respiratory and intrathoracic organs | C30–C31, C37–C39 | 0.93 (0.25–2.37) | 0.90 (0.24–2.29) |
| Bone and skin | |||
| Malignant neoplasms ofbone and articular cartilage | C40–C41 | 0.99 (0.20–2.89) | 1.08 (0.22–3.16) |
| Malignant melanoma of skin | C43 | 0.58 (0.01–3.21) | 0.49 (0.01–2.71) |
| Other malignant neoplasm of skin | C44 | 1.66 (0.83–2.97) | 1.85 (0.92–3.31) |
| Malignant neoplasms of mesothelial and soft tissue | C45–C49 | 0.61 (0.17–1.56) | 0.59 (0.16–1.52) |
| Genitourinary tract system | |||
| Malignant neoplasm of prostate | C61 | 1.03 (0.74–1.39) | 1.36 (0.98–1.85) |
| Other malignant neoplasms of male genital organs | C60, C62–C63 | 0.42 (0.01–2.35) | 0.42 (0.01–2.34) |
| Malignant neoplasm of bladder | C67 | 0.84 (0.46–1.42) | 0.73 (0.40–1.22) |
| Other malignant neoplasms of urinary tract | C64–C66, C68 | 1.06 (0.73–1.49) | 1.02 (0.70–1.43) |
| Nervous system | |||
| Malignant neoplasm of eye and adnexa | C69 | None | None |
| Malignant neoplasm of brain | C71 | 0.75 (0.30–1.55) | 0.85 (0.34–1.75) |
| Malignant neoplasm of other parts of central nervous system | C70, C72 | 0.80 (0.02–4.46) | 0.72 (0.02–3.98) |
| Lymphoid and hematopoietic system | |||
| Hodgkin disease | C81 | 1.08 (0.03–5.99) | 0.71 (0.02–3.93) |
| Non-Hodgkin lymphoma | C82–C86 | 0.95 (0.54–1.54) | 0.91 (0.52–1.47) |
| Leukemia | C91–C95 | 1.86 (1.15–2.84) | 1.77 (1.10–2.70) |
| Other malignant neoplasms of lymphoid, hematopoietic and related tissue | C88–C90, C96 | 0.92 (0.37–1.89) | 1.05 (0.42–2.16) |
| Other | |||
| Malignant neoplasm of other, ill-defined, secondary, unspecified, and multiple sites | C73–C80, C97 | 1.64 (1.45–1.85) | 1.68 (1.49–1.89) |
Figure 1Age-standardized incidence rate (95% confidence interval) of cancers referenced with the government employee.
Figure 2Age-standardized incidence rate (95% confidence interval) of cancers referenced with whole employee.
The age-standardized Incidence Ratios (SIR) and 95% confidence interval (CI) of the air transportation industry female workers for cancers according to reference group.
| Cancer | ICD-10 | Reference, SIR (95% CI) for Cancers | |
|---|---|---|---|
| Government Employee | Whole Employee | ||
| All cancer | 2.27 (1.79–2.84) | 2.09 (1.65–2.62) | |
| Gastrointestinal tract system | |||
| Malignant neoplasms of lip, oral cavity, and pharynx | C00–C14 | None | None |
| Malignant neoplasm of esophagus | C15 | None | None |
| Malignant neoplasm of stomach | C16 | 0.29 (0.01–1.61) | 0.28 (0.01–1.55) |
| Malignant neoplasm of colon | C18 | None | None |
| Malignant neoplasm of rectosigmoid junction, rectum, anus, and anal canal | C19–C21 | None | None |
| Malignant neoplasm of liver and intrahepatic bile ducts | C22 | None | None |
| Malignant neoplasm of pancreas | C25 | None | None |
| Other malignant neoplasm of digestive organs | C17, C23–C24, C26 | None | None |
| Respiratory system | |||
| Malignant neoplasm of larynx | C32 | None | None |
| Malignant neoplasm of trachea, bronchus, and lung | C33–C34 | 2.76 (0.76–7.06) | 3.07 (0.84–7.85) |
| Other malignant neoplasms of respiratory and intrathoracic organs | C30–C31, C37–C39 | None | None |
| Bone and skin | |||
| Malignant neoplasms ofbone and articular cartilage | C40–C41 | None | None |
| Malignant melanoma of skin | C43 | None | None |
| Other malignant neoplasm of skin | C44 | None | None |
| Malignant neoplasms of mesothelial and soft tissue | C45–C49 | None | None |
| Genitourinary tract system | |||
| Malignant neoplasm of breast | C50 | 1.18 (0.70–1.87) | 1.38 (0.82–2.18) |
| Malignant neoplasm of cervixuteri | C53 | 0.97 (0.02–5.40) | 0.49 (0.01–2.74) |
| Malignant neoplasms of other and unspecified parts of uterus | C54–C55 | 0.74 (0.02–4.11) | 0.78 (0.02–4.33) |
| Other malignant neoplasms of female genital organs | C51–C52, C56–C58 | 0.54 (0.01–3.02) | 0.60 (0.02–3.37) |
| Malignant neoplasm of bladder | C67 | 7.16 (0.18–39.90) | 6.93 (0.8–38.61) |
| Other malignant neoplasms of urinary tract | C64–C66, C68 | 3.24 (0.39–11.72) | 3.71 (0.45–13.40) |
| Nervous system | |||
| Malignant neoplasm of eye and adnexa | C69 | None | None |
| Malignant neoplasm of brain | C71 | None | None |
| Malignant neoplasm of other parts of central nervous system | C70, C72 | None | None |
| Lymphoid and hematopoietic system | |||
| Hodgkin disease | C81 | None | None |
| Non-Hodgkin lymphoma | C82–C86 | None | None |
| Leukemia | C91–C95 | 2.00 (0.05–11.16) | 1.62 (0.04–9.00) |
| Other malignant neoplasms of lymphoid, hematopoietic and related tissue | C88–C90, C96 | None | None |
| Other | |||
| Malignant neoplasm of other, ill-defined, secondary, unspecified, and multiple sites | C73–C80, C97 | 1.43 (1.06–1.89) | 1.57 (1.16–2.06) |